NCT03695744 2023-07-10
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
Phase 2 Unknown
Clinical Trials
28 trialsNCT03641456 2023-06-18
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Sun Yat-sen University
Phase 2 Unknown
NCT05432414 2023-01-31
PVd Versus Vd in NDMM Patients With RI
RenJi Hospital
Phase 2 Unknown
NCT04277845 2022-09-09
KMM1910
Samsung Medical Center
Phase 2 Unknown
NCT04474938 2022-05-10
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05147493 2022-03-29
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Phase 2 Unknown
NCT01965977 2020-10-23
Borma
Samsung Medical Center
Phase 2 Unknown
NCT03509246 2020-01-14
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients
Seoul National University Hospital
Phase 2 Unknown
NCT04061772 2019-08-20
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT02542111 2017-11-14
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT03335098 2017-11-07
BOMB-THROW
Seoul National University Hospital
Phase 2 Unknown
NCT02086942 2017-08-29
Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.
Jinling Hospital, China
Phase 2 Unknown
NCT03016988 2017-01-11
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Fujian Medical University
Phase 2 Unknown
NCT02093910 2014-11-19
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy
Sun Yat-sen University
Phase 2 Unknown
NCT00389701 2014-01-10
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
National Cancer Institute (NCI)
Phase 2 Unknown
NCT02027220 2014-01-06
Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT00742404 2013-12-18
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01950611 2013-09-25
PIAPL
Christian Medical College, Vellore, India
Phase 2 Unknown
NCT00996385 2011-10-31
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Columbia University
Phase 2 Unknown
NCT01114048 2011-09-22
KMM-97
Chonnam National University Hospital
Phase 2 Unknown
NCT01328236 2011-09-22
Bortezomib
Clinical Service, China
Phase 2 Unknown
NCT00508209 2010-06-22
Bortezomib and High-dose Melphalan at Myeloma Relapse
Nordic Myeloma Study Group
Phase 2 Unknown
NCT00510939 2009-08-14
HEMOS AML 0106
University of Bologna
Phase 2 Unknown
NCT00438841 2009-03-13
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00261612 2006-10-18
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
Medical University of Vienna
Phase 2 Unknown
NCT00378755 2006-09-22
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
Korean Multiple Myeloma Working Party
Phase 2 Unknown
NCT00319865 2006-04-27
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Korean Multiple Myeloma Working Party
Phase 2 Unknown
NCT00311337 2006-04-05
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
University of Wuerzburg
Phase 2 Unknown